Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Share-based Compensation (2019 - 2025)

IDEAYA Biosciences' Share-based Compensation history spans 7 years, with the latest figure at $11.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 24.33% year-over-year to $11.8 million; the TTM value through Dec 2025 reached $46.1 million, up 32.72%, while the annual FY2025 figure was $46.1 million, 32.72% up from the prior year.
  • Share-based Compensation for Q4 2025 was $11.8 million at IDEAYA Biosciences, down from $12.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.2 million in Q3 2025 and bottomed at $1.9 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $4.8 million (2023), against an average of $6.0 million.
  • The largest annual shift saw Share-based Compensation surged 153.03% in 2021 before it rose 21.92% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.1 million in 2021, then surged by 44.14% to $3.0 million in 2022, then surged by 61.28% to $4.8 million in 2023, then surged by 97.69% to $9.5 million in 2024, then increased by 24.33% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Share-based Compensation are $11.8 million (Q4 2025), $12.2 million (Q3 2025), and $11.9 million (Q2 2025).